Chinese Innovative Drugs Surge Ahead: Fosun Pharma’s License-Out Deals Exceed USD 60 Billion
Source: DengYueMed On October 18, Chen Yuqing, Chairman of Fosun Pharma, stated at an event…
News
China’s Pharmaceutical Breakthroughs Go Global: Behind the $45 Billion Boom and the Next Great Test
China’s Pharmaceutical Innovation Goes Global: Challenges and New Momentum In the first five months of…
Breaking free from pharmaceutical tariffs! Can innovative drugs accelerate overseas expansion by 2025?
On May 6, the U.S. government announced plans to unveil new pharmaceutical tariff measures within…
Top 10 China Pharma Deals 2025: $40B in Global Innovation Exports
In the first half of 2025, China’s innovative drug license-out deals surpassed USD 15 billion,…
Navigating the Global Supply Chain: Your Strategic Guide to a China Drug Import and Export Wholesaler
In an increasingly interconnected pharmaceutical landscape, the role of a reliable China drug import and…
Onradivir Tablets Officially Approved by NMPA丨Marking a Major Breakthrough in Influenza Treatment
Guangdong, China — May 22, 2025 丨 The National Medical Products Administration (NMPA) has officially…
Suvemcitug Injection Approval in China丨Brings a New Treatment Option for Platinum-Resistant Ovarian Cancer
On July 3, 2025, Simcere Pharmaceutical Group Limited’s innovative drug subsidiary, Simcere, announced that its…
Global First Dual-Target COVID-19 Drug Olgotrelvir Sodium Capsules Approved by China’s NMPA
Recently, the National Medical Products Administration (NMPA) granted conditional approval for Olgotrelvir Sodium Capsules, a…
Firsekibart Injection Approved by NMPA: A Breakthrough IL-1β Antibody Offering Long-Acting Relief for Acute Gouty Arthritis
The National Medical Products Administration (NMPA) has officially approved Firsekibart Injection, a Class 1 innovative…
How China Ensures the Quality and Safety of Its Exported Pharmaceuticals
With the rapid globalization of China’s pharmaceutical industry, the question of how China ensures the…
Copyright@ 2016-2024 Hong Kong Deng Yue Med Al Rights